Merck & Co., Inc.
Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%
Merck ProQuad by Year
ProQuad (measles, mumps, rubella and varicella virus vaccine) — Worldwide sales ($M) ($M)
Merck ProQuad: $930M in FY2025, up 1.1% from a year earlier. That is the highest of the 9 years on record here.
Where the FY2025 figure comes from
“|| ProQuad | 930 | 1 | % | 1 | % | 920 | 6 | % | 6 | % | 870”
Source: Form 10-K (mrk-20251231.htm, filed 2026-02-24) ↗
Reported in Form 10-Q / 10-K MD&A Pediatric Vaccines Disclosure (Q4 derived as Full Year − 9M).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | ProQuad (measles, mumps, rubella and varicella virus vaccine) — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 930 | +1.1% | Form 10-K (mrk-20251231.htm, filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 920 | +5.7% | Form 10-K (mrk-20251231.htm, filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 870 | +3.7% | Form 10-K (mrk-20251231.htm, filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 839 | +8.5% | Form 10-K (mrk-20241231.htm, filed 2025-02-25) ↗ |
| FY2021 | Dec 31, 2021 | 773 | +14.0% | Form 10-K (mrk-20231231.htm, filed 2024-02-26) ↗ |
| FY2020 | Dec 31, 2020 | 678 | -10.3% | Form 10-K (mrk-20221231.htm, filed 2023-02-24) ↗ |
| FY2019 | Dec 31, 2019 | 756 | +27.5% | Form 10-K (mrk-20211231.htm, filed 2022-02-25) ↗ |
| FY2018 | Dec 31, 2018 | 593 | +12.3% | Form 10-K (mrk-20201231.htm, filed 2021-02-25) ↗ |
| FY2017 | Dec 31, 2017 | 528 | – | Form 10-K (mrk1231201910k.htm, filed 2020-02-26) ↗ |
Breakdown
What makes up proQuad
Cite this data
StockData. (2026). Merck ProQuad ($M), annual FY2017–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-proquad
See every metric in the Merck KPI table. Data updated Oct 26, 2026.
See a number that looks wrong?